Skip to main content
Advertisement
Advertisement
EVGN
EVGN logo
EVOGENE LTD.
0.34
USD
Sponsored
0.00
+0.56%
Nov 18, 09:40 UTC -5
Open

EVOGENE LTD. (EVGN) Earnings

EVGN Earnings Reports

Positive Surprise Ratio

EVGN beat 16 of 32 last estimates.

50%

Next Report

Today BMO
Date of Next Report
Nov 18, 2026
Estimate for Q3 26 (Revenue/ EPS)
$372.30K
/
-$0.19
Implied change from Q2 26 (Revenue/ EPS)
+7.29%
/
+35.71%
Implied change from Q3 25 (Revenue/ EPS)
+19.33%
/
-143.18%

EVOGENE LTD. earnings per share and revenue

On Aug 18, 2026, EVGN reported earnings of -0.14 USD per share (EPS) for Q2 26, beating the estimate of -0.27 USD, resulting in a 49.16% surprise. Revenue reached 347.00 thousand, compared to an expected 331.50 thousand, with a 4.68% difference. The market reacted with a +4.04% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.19 USD, with revenue projected to reach 372.30 thousand USD, implying an increase of 35.71% EPS, and increase of 7.29% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Rein Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
logo
Instil Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.62
Surprise
-261.09%
logo
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+4.59%
logo
Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%
logo
Dare Bioscience, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.26
Actual
-$0.18
Surprise
+32.13%
logo
GT Biopharma Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$2.54
Actual
-$1.98
Surprise
+22.35%
logo
Lantern Pharma Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.81
Surprise
-126.89%
logo
Pulmatrix, Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-
Actual
-$0.34
Surprise
-
logo
HCW Biologics Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.37
Actual
-$1.53
Surprise
-11.11%
logo
Aptevo Therapeutics Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.78
Actual
-$5.19
Surprise
-36.96%
FAQ
For Q2 2026, EVOGENE LTD. reported EPS of -$0.14, beating estimates by 49.16%, and revenue of $347.00K, 4.68% above expectations.
The stock price moved up 4.04%, changed from $0.56 before the earnings release to $0.58 the day after.
The next earning report is scheduled for Nov 18, 2026.
Based on -- analysts, EVOGENE LTD. is expected to report EPS of -$0.19 and revenue of $372.30K for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement